U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H5I3NO3.Na
Molecular Weight 578.8441
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACETRIZOATE SODIUM

SMILES

[Na+].CC(=O)NC1=C(I)C=C(I)C(C([O-])=O)=C1I

InChI

InChIKey=UCPVOMHRDXMAIZ-UHFFFAOYSA-M
InChI=1S/C9H6I3NO3.Na/c1-3(14)13-8-5(11)2-4(10)6(7(8)12)9(15)16;/h2H,1H3,(H,13,14)(H,15,16);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C9H5I3NO3
Molecular Weight 555.8543
Charge -1
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Acetrizoic acid (trade names Gastrografina, Urografina in Portugal) is a palatable lemon-flavored water-soluble iodinated radiopaque X-ray contrast medium for oral or rectal administration only. Acetrizoic acid is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. Administration of hypertonic Gastrografin solutions may lead to hypovolemia and hypotension due to fluid loss from the intestine.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Gastrografina
Diagnostic
Gastrografina
Diagnostic
Gastrografina

Cmax

ValueDoseCo-administeredAnalytePopulation
248 ng/mL
50 mg single, oral
ACETRIZOIC ACID plasma
Homo sapiens
416 ng/mL
50 mg single, oral
ACETRIZOIC ACID plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1342 ng × h/mL
50 mg single, oral
ACETRIZOIC ACID plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2.3 h
50 mg single, oral
ACETRIZOIC ACID plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
50 mg single, oral
ACETRIZOIC ACID plasma
Homo sapiens

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Adult oral dosage may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature of the examination and the size of the patient. For infants and children less than 5 years of age, 30 mL (11 g iodine) are usually adequate; for children 5 to 10 years of age, the suggested dose is 60 mL (22 g iodine).
Route of Administration: Oral
In Vitro Use Guide
Blood was taken from the femoral artery of heparinized dogs (heparin 500 I.U./kg I.V.). Immediately after collection, the blood samples were incubated for 45 sec. at 37 C with the solutions of the ACETRIZOIC ACID;the final concentrations of the contrast media in the incubation medium were 220 mM. This was done by adding to aliquots of whole blood the solutions oЈ contrast media, which were hyperosmolar to plasma (2200 mOsm).
Substance Class Chemical
Record UNII
5GF4B2I1DD
Record Status Validated (UNII)
Record Version